24th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma is organized by Physicians' Education Resource, LLC (PER) and will be held from Feb 27 - Mar 01, 2020 at Eden Roc Miami Beach, Miami Beach, Florida, Unites States of America.
This educational activity is directed toward community-based hematologists and medical oncologists, as well as fellows involved in the treatment and management of patients with hematologic malignancies. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of hematologic malignancies may also participate.
Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 18.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
To earn an additional 4.0 AMA PRA Category 1 Credits™, attend the CAR T Preconference Workshop.
Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 18.0 Contact Hours.
Nurse Practitioner Session (Educational Session and Networking for Advanced Practitioners: Clinical Pearls for Practice)
This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards.
This program is accredited for 2.0 contact hours which includes 2.0 hours of pharmacology in partnership with Partners in Healthcare Education, LLC. Partners in Healthcare Education, LLC is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education; Provider Number: 031206.
Now in its 24th year, the annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma provides practitioners who manage hematologic malignancies with the practical tools to translate emerging data into the best therapy for their patients, to personalize care according to patient and tumor characteristics, and to apply novel treatment strategies to improve patient outcomes.
We are pleased to feature expanded coverage on chimeric antigen receptor (CAR) T cells and immunotherapy in 2020. First, a full afternoon session on Thursday, February 27, 2020, will be dedicated to addressing advances in CAR T-cell therapy for hematologic malignancies, as well as strategies to overcome treatment resistance. Next, sessions on Friday, Saturday, and Sunday will focus on methods to apply state-of-the-art treatment strategies in your clinical practice setting. This engaging and highly interactive meeting will provide ample opportunity for attendees to interact with internationally renowned experts in the management of leukemias, lymphomas, myeloma, myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPNs), and benign hematologic malignancies. Our faculty will distill practice-changing evidence and recommend how to put this information into clinical context, so that you may apply it to real-world patient-care scenarios. The discussion will also focus on how to proactively mitigate and manage treatment-related toxicities associated with new cellular therapies.
Interspersed throughout the meeting are sessions of Medical Crossfire®, a nationally recognized healthcare communication platform for debate, discussion, and peer exchange. These sessions will provide attendees with the opportunity to explore some of the most challenging clinical situations in the management of hematologic malignancies—treatment scenarios with multiple potential approaches.
This dynamic Congress will inspire participants to reflect on and share the new information they have learned, and to apply these new practices in the clinical setting, with the ultimate goal of improving patient outcomes.
Hot Topics for 2020
• The potential for cell-based therapy to change treatment paradigms in hematologic malignancies
• Best practices for patients with non-Hodgkin and Hodgkin lymphoma
• Recent data on, and approval of, targeted agent-based therapies for patients with chronic lymphocytic leukemia
• State-of-the-art approaches for patients with smoldering and symptomatic multiple myeloma
• Incorporation of novel agents in treatment algorithms for patients with acute leukemias
• Emerging agents for patients with MPNs
• The role of assessment of measurable/minimal residual disease
• How to navigate the value-based landscape of healthcare
Benefits of Attending
• Stay up-to-date with emerging and recently approved agents and approaches for patients with hematologic malignancies
• Learn about molecular profiling and other emerging techniques for risk assessment
• Improve your competence in managing treatment-related adverse events
• Network with your peers and internationally renowned experts in hematology/oncology
|Contact No. :||+1 609-378-3701
|Registration Type||End Date||Price|
|Physicians - Regular Fee||26 Feb,2020||USD 339.00|
|Physicians - On Site Fee Fee||27 Feb,2020||USD 399.00|
|Fellows - Regular Fee||26 Feb,2020||USD 279.00|
|Fellows - On Site Fee Fee||27 Feb,2020||USD 319.00|
|Nurses, PAs, Other Health Care Professionals - Regular Fee||26 Feb,2020||USD 199.00|
|Nurses, PAs, Other Health Care Professionals - On Site Fee Fee||27 Feb,2020||USD 249.00|
|Industry - Regular Fee||26 Feb,2020||USD 799.00|
|Industry - On Site Fee Fee||27 Feb,2020||USD 899.00|